Please assess the completion status of the following clinical trial:

Trial Title: Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men or postmenopausal women~* 55 years of age or older~* Diagnosis of MCI due to AD or mild AD~* MMSE \> 20 at screen~* Capacity to provide informed consent~* Residing in the community with a caregiver able to accompany the patient to clinic visits~* No medical contraindications to participation~* Willingness to comply with study procedures~Exclusion Criteria:~* Use of benzodiazepines, sedative/hypnotics, anticonvulsants, antipsychotics, and other drugs that might interact with the GABA-A receptor complex~* Seizure disorder, history of stroke, focal brain lesion, traumatic brain injury, substance abuse, malignancy~* Clinically significant laboratory or ECG abnormality~* MRI indicative of any other significant abnormality, including but not limited to evidence of a cerebral contusion, encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or space occupying lesions~* Any condition that would contraindicate an MRI such as the presence of metallic objects in the eyes, skin, heart, or body

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allopregnanolone 2 mg (Type: EXPERIMENTAL): Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
- Allopregnanolone 4 mg (Type: EXPERIMENTAL): Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
- Allopregnanolone 6-18 mg (Type: EXPERIMENTAL): Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Drug: Placebo injection (intravenous solution) once per week for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).